Types Of Personality Disorders And Its Therapeutic Measures: An Overview
DOI:
https://doi.org/10.52783/jns.v14.2964Keywords:
Personality disorders, cluster, social communication, lifestyle, Cluster AAbstract
Personality disorders (PDs) represent a significant global public health concern, with an estimated 10% of the population affected. In the UK, prevalence studies indicate PD diagnoses in 38% of females and 30% of males (2009-2010). According to the Indian Psychiatric Society, 75% of the population exhibits severe personality deviations, a defining feature of PDs. Characterized by maladaptive personality traits that severely impair daily functioning, PDs are associated with poor life quality, mental health comorbidities, and an elevated risk of premature death. PDs typically manifest in childhood or early adulthood and are influenced by genetic, environmental, and psychological factors. Clinical manifestations include social communication difficulties, emotional instability, depression, anxiety, and phobias. The DSM-5 categorizes PDs into three clusters: Cluster A (suspicious), Cluster B (emotional and impulsive), and Cluster C (anxious). This review aims to provide an overview of PDs and offer guidance on their identification, diagnosis, and treatment by healthcare professionals.
Downloads
Metrics
References
Fitriani A, Supradewi R. Desensitisasi Sistematis dengan Relaksasi Zikir untuk Mengurangi Gejala Kecemasan pada Kasus Gangguan Fobia. Philanthr J Psychol. 2019;3.
Maddiboyina B, Ramaiah, Nakkala RK, Roy H. Perspectives on cutting-edge nanoparticulate drug delivery technologies based on lipids and their applications. Chem Biol Drug Des. 2023.
Roy H, Maddiboyina B, Rahaman SA, Singh PK, Tripathi AK, Srivastava SK, et al. Implementation and effect estimation by Taguchi orthogonal array design for Metoprolol Sustained Release Tablets. Smart Sci [Internet]. 2023; 11:649–60. Available from: https://doi.org/10.1080/23080477.2023.2236778
Maddiboyina B, Roy H, Nakkala RK, Gandhi S, Kavisri M, Moovendhan M. Formulation, optimization and characterization of raloxifene hydrochloride loaded PLGA nanoparticles by using Taguchi design for breast cancer application. Chem Biol Drug Des. 2023.
Santana GL, Coelho BM, Wang YP, Filho ADPC, Viana MC, Andrade LH. The epidemiology of personality disorders in the Sao Paulo Megacity general population. PLoS One. 2018;13.
Nakkala RK, Maddiboyina B, Bolisetti SC, Roy H. Duloxetine hydrochloride enteric-coated pellets in capsules with delayed release: formulation and evaluation. Smart Sci. 2023.
Moran P, Jenkins R, Tylee A, Blizard R, Mann A. The prevalence of personality disorder among UK primary care attenders. Acta Psychiatr Scand. 2000;102.
Maddiboyina B, Roy H, Ramaiah M, Sarvesh CN, Kosuru SH, Nakkala RK, et al. Methicillin-resistant Staphylococcus aureus: novel treatment approach breakthroughs. Bull Natl Res Cent [Internet]. 2023; 47:95. Available from: https://doi.org/10.1186/s42269-023-01072-3
Vasam M, Maddiboyina B, Talluri C, Alagarsamy S, Gugulothu B, Roy H. Formulation, Characterization, and Taguchi Design Study of Eplerenone Lipid-Based Solid Dispersions Integrated with Gelucire. Bionanoscience [Internet]. 2023; Available from: https://doi.org/10.1007/s12668-023-01102-4
Zhang T, Wang L, Good MJD, Good BJ, Chow A, Dai Y, et al. Prevalence of personality disorders using two diagnostic systems in psychiatric outpatients in Shanghai, China: A comparison of uni-axial and multi-axial formulation. Soc Psychiatry Psychiatr Epidemiol. 2012;47.
Jhawat V, Gulia M, Gupta S, Maddiboyina B, Dutt R. Integration of pharmacogenomics and theranostics with nanotechnology as quality by design (QbD) approach for formulation development of novel dosage forms for effective drug therapy. J. Control. Release. 2020.
Maddiboyina B, Vanamamalai HK, Roy H, Ramaiah, Gandhi S, Kavisri M, et al. Food and drug industry applications of microalgae Spirulina platensis: A review. J Basic Microbiol. 2023.
Maddina BY, Asthana GS, Asthana A. A Review on current scenario of spirulina drug delivery systems. World J Pharm Sci. 2016; 4:86–9.
Cave GF. A new proposal classifying personality disorders: The international classification of diseases ICD-11. Rev. Chil. Neuropsiquiatr. 2018.
Sood S, Maddiboyina B, Rawat P, Garg AK, Foudah AI, Alam A, et al. Enhancing the solubility of nitazoxanide with solid dispersions technique: formulation, evaluation, and cytotoxicity study. J Biomater Sci Polym Ed. 2020; 12:22–38.
Maddiboyina B, Nakkala RK, Sivaraman G. Biomass-Derived Mesoporous Carbon Nanomaterials for Drug Delivery and Imaging Applications. Biomass-Derived Carbon Mater. 2023.
Maddiboyina B, Jhawat V, Sivaraman G, Sunnapu O, Nakkala RK, Naik MH, et al. Formulation development and characterization of controlled release core-in-cup matrix tablets of venlafaxine hcl. Curr Drug ther. 2020;15.
Wagner T, Assmann N, Köhne S, Schaich A, Alvarez-Fischer D, Borgwardt S, et al. The societal cost of treatment-seeking patients with borderline personality disorder in Germany. Eur Arch Psychiatry Clin Neurosci. 2022;272.
Maddiboyina B, Desu PK, Vasam M, Challa VT, Surendra A V., Rao RS, et al. An insight of nanogels as novel drug delivery system with potential hybrid nanogel applications. J. Biomater. Sci. Polym. Ed. 2021.
Jhawat V, Gulia M, Maddiboyina B, Dutt R, Gupta S. Fate and Applications of Superporous Hydrogel Systems: A Review. Curr Nanomedicine. 2020;10.
Maddiboyina B, Jhawat V, Desu PK, Gandhi S, Nakkala RK, Singh S. Formulation and Evaluation of Thermosensitive Flurbiprofen In Situ Nano Gel for the Ocular Delivery. J Biomater Sci Polym Ed. 2021;1–12.
Maddiboyina B, Hanumanaik M, Nakkala RK, Jhawat V, Rawat P, Alam A, et al. Formulation and evaluation of gastro-retentive floating bilayer tablet for the treatment of hypertension. Heliyon [Internet]. 2020;6: e05459. Available from: https://doi.org/10.1016/j.heliyon.2020.e05459
Grenyer BFS, Ng FYY, Townsend ML, Rao S. Personality disorder: A mental health priority area. Aust. N. Z. J. Psychiatry. 2017.
Garg AK, Maddiboyina B, Alqarni MHS, Alam A, Aldawsari HM, Rawat P, et al. Solubility enhancement, formulation development and antifungal activity of luliconazole niosomal gel-based system. J Biomater Sci Polym Ed. 2021.
Mungo A, Hein M, Hubain P, Loas G, Delhaye M. Borderline personality disorder in adolescence. Rev Med Brux. 2019;40.
Maddiboyina B, Jhawat V, Nakkala RK, Desu PK, Gandhi S. Design expert assisted formulation, characterization and optimization of microemulsion based solid lipid nanoparticles of repaglinide. Prog Biomater. 2021;10.
Roy H, Nayak BS, Maddiboyina B, Nandi S. Chitosan based urapidil microparticle development in approach to improve mechanical strength by cold hyperosmotic dextrose solution technique. J Drug Deliv Sci Technol [Internet]. 2022; 76:103745. Available from: https://www.sciencedirect.com/science/article/pii/S1773224722006566
Kulacaoglu F, Kose S. Borderline personality disorder (BPD): During vulnerability, chaos, and awe. Brain Sci. 2018.
Roy H, Srungarapati S, Gade NJ, Gummadi A, Marry Karunasree BK, Dakkumalla M, et al. Citicoline loaded nanoemulsion enriched with D-alpha-Tocopherol acetate and protein: Formulation and in-silico study. J Drug Deliv Sci Technol [Internet]. 2023; 82:104340. Available from: https://www.sciencedirect.com/science/article/pii/S1773224723001922
BALAJI MADDIBOYINA; RAMYA KRISHNA NAKKALA; VINOD KUMAR KOKKILAGADDA. Preparation and Evaluation of Esomeprazole Enteric Coated Tablets. Ijppr. 2020; 18:16–30.
Lee R. Mistrustful and Misunderstood A Review of Paranoid Personality Disorder. Curr Behav Neurosci reports. 2017; 4:151–165.
Cook ML, Zhang Y, Constantino JN. On the Continuity between Autistic and Schizoid Personality Disorder Trait Burden: A Prospective Study in Adolescence. J Nerv Ment Dis. 2020;208.
Dong F, Liu J, Hodgson NA, Medoff-Cooper B. Early life factors of schizotypal personality disorder in adolescents: A systematic review. J. Psychiatr. Ment. Health Nurs. 2021.
Black DW. The natural history of antisocial personality disorder. Can. J. Psychiatry. 2015.
Trull TJ, Freeman LK, Vebares TJ, Choate AM, Helle AC, Wycoff AM. Borderline personality disorder and substance use disorders: An updated review. Borderline Personal. Disord. Emot. Dysregulation. 2018.
Novais F, Araújo A, Godinho P. Historical roots of histrionic personality disorder. Front. Psychol. 2015.
Weinberg I, Ronningstam E. Dos and don’ts in treatments of patients with narcissistic personality disorder. J Pers Disord. 2020;34.
Lampe L, Malhi GS. Avoidant personality disorder: Current insights. Psychol. Res. Behav. Manag. 2018.
Bano Z, Shahzadi A. Dependent personality disorder scale: Development and reliability study. Khyber Med Univ J. 2020;12.
Gulin S, Ellbin S, Jonsdottir IH, Lindqvist Bagge AS. Is obsessive–compulsive personality disorder related to stress-related exhaustion? Brain Behav. 2021;11.
Petito A, Altamura M, Iuso S, Padalino FA, Sessa F, D’Andrea G, et al. The relationship between personality traits, the 5HTT polymorphisms, and the occurrence of anxiety and depressive symptoms in elite athletes. PLoS One. 2016;11.
Balaji M, Ramyakrishna N, Hanumanaik M. Formulation Development and Characterization of Enteric Coated Tablets of Lansoprazole. der Pharm Lett [Internet]. 2020; 12:22–38. Available from: www.scholarsresearchlibrary.com
Baskin-Sommers AR, Curtin JJ, Newman JP. Altering the Cognitive-Affective Dysfunctions of Psychopathic and Externalizing Offender Subtypes with Cognitive Remediation. Clin Psychol Sci a J Assoc Psychol Sci. 2015;3:45–57.
Maddiboyina B, Shanmugapriya J, Rasala S, Sivaraman G. Bioinspired Nanomaterials for Drug Delivery. Bioinspired Nanomater Synth Emerg Appl [Internet]. Materials. Materials Research Forum LLC; 2021. p. 63–95. Available from: https://www.mrforum.com/product/9781644901571-3
Beeney JE, Hallquist MN, Clifton AD, Lazarus SA, Pilkonis PA. Social disadvantage and borderline personality disorder: A study of social networks. Personal Disord. 2018; 9:62–72.
Singh S, Numan A, Maddiboyina B, Arora S, Riadi Y, Md S, et al. The emerging role of immune checkpoint inhibitors in the treatment of triple-negative breast cancer. Drug Discov. Today. 2021.
Ward RK. Assessment and management of personality disorders. Am Fam Physician. 2004;70.
Walter M, Gunderson JG, Zanarini MC, Sanislow CA, Grilo CM, McGlashan TH, et al. new onsets of substance use disorders in borderline personality disorder over 7 years of follow-ups: Findings from the Collaborative Longitudinal Personality Disorders Study. Addiction. 2009;104.
Patel J, Kumar GS, Roy H, Maddiboyina B, Leporatti S, Bohara RA. From nature to nanomedicine: bioengineered metallic nanoparticles bridge the gap for medical applications. Discov Nano [Internet]. 2024; 19:85. Available from: https://doi.org/10.1186/s11671-024-04021-9
Fok MLY, Hayes RD, Chang CK, Stewart R, Callard FJ, Moran P. Life expectancy at birth and all-cause mortality among people with personality disorder. J Psychosom Res [Internet]. 2012; 73:104–7. Available from: http://dx.doi.org/10.1016/j.jpsychores.2012.05.001
Colom J, Szerman N, Sabater E, Ferre F, Pascual F, Gilabert-Perramon A, et al. Study to determine relevant health outcome measures in opioid use disorder: Multicriteria decision analysis. Adicciones. 2021;33.
Ramsay G, Jolayemi A. Personality Disorders Revisited: A Newly Proposed Mental Illness. Cureus. 2020.
National Confidential Inquiry. Safer Care for Patients with Personality Disorder. Heal Qual Improv Partnersh. 2018;35.
Skodol AE. Personality pathology and population health. The Lancet Psychiatry. 2016.
Moran P, Romaniuk H, Coffey C, Chanen A, Degenhardt L, Borschmann R, et al. The influence of personality disorder on the future mental health and social adjustment of young adults: a population-based, longitudinal cohort study. The Lancet Psychiatry. 2016;3.
Tyrer P, Reed GM, Crawford MJ. Classification, assessment, prevalence, and effect of personality disorder. Lancet. 2015.
Barrett B, Byford S. Costs and outcomes of an intervention programme for offenders with personality disorders. Br J Psychiatry. 2012;200.
Tang A, Crawford H, Morales S, Degnan KA, Pine DS, Fox NA. Infant behavioral inhibition predicts personality and social outcomes three decades later. Proc Natl Acad Sci U S A. 2020;117.
Kiel N, Bruckdorfer R, Petermann F, Reinelt T. Temperament in early childhood and developmental externalizing disorders: Clinical implications. Zeitschrift fur Psychiatr Psychol und Psychother. 2018;66.
Gulia M, Nishal S, Maddiboyina B, Dutt R, Kumar Desu P, Wadhwa R, et al. Physiological Pathway, diagnosis and nanotechnology-based treatment strategies for ovarian Cancer: A review. Med Omi [Internet]. 2023; 8:100020. Available from: https://www.sciencedirect.com/science/article/pii/S2590124923000019
Digman JM. Personality structure: emergence of the five-factor model. Annu Rev Psychol. 1990;41.
Graziano WG. Personality Development: An Introduction toward Process Approaches to Long-Term Stability and Change in Persons. J. Pers. 2003.
Slobodskaya HR, Kornienko OS. Age and gender differences in personality traits from early childhood through adolescence. J Pers. 2021;89.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
